Researchers Uncover New Complexities in Human Hearing
Researchers identified a previously unknown set of cochlear modes that refine our understanding of how the human ear assesses sounds.
Researchers identified a previously unknown set of cochlear modes that refine our understanding of how the human ear assesses sounds.
The majority of cochlear implant recipients develop new bone formation that adversely affects long-term hearing preservation, according to a study appearing in Radiology.
Scientists from the USC Stem Cell laboratory of Neil Segil have identified a natural barrier to the regeneration of the inner ear sensory cells, which are lost in hearing and balance disorders.
Cooling the sensitive tissues of the inner ear before and during a cochlear implant surgery may lead to better hearing outcomes, according to a University of Miami Health System and College of Engineering researcher who is leading a collaborative team developing this therapeutic approach.
Read MoreThe data show hearing improvements in adults with acquired sensorineural hearing loss (SNHL) and the “first known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy,” according to Frequency.
Read MoreWe hear sounds in part because tiny filaments inside our inner ears help convert voices, music, and noises into electrical signals that are sent to our brains for processing. Now, scientists have mapped and simulated those filaments at the atomic level, a discovery that shed lights on how the inner ear works and that could help researchers learn more about how and why people lose the ability to hear.
Read MoreAt the end of two weeks, results showed that for the COVID-infected group, high-frequency pure-tone thresholds as well as the TEOAE amplitudes were significantly worse in the test group, indicating damage to outer ear hair cells.
Read MoreVertidiag is said to have developed a technical platform to induce controlled vestibular disorders and to measure their functional impacts. This platform uses behavioral pharmacology, along with a battery of cellular and molecular biology tools that support the understanding of the mechanisms of action of potential drug candidates.
Read MoreFX-322 is Frequency’s lead product candidate, designed to regenerate auditory sensory hair cells in the cochlea and improve hearing in patients with sensorineural hearing loss (SNHL).
Read MoreCochlear Limited (ASX: COH), a company that specializes in implantable hearing solutions,...
Read MoreTodays more competitive hearing care market makes it especially critical for practices to establish strong relationships with local physicians and heathcare providers.
Read MoreCochlear Limited (ASX: COH), an implantable hearing solutions company, announced the US Food and...
Read MoreUsing zebrafish as a proxy, scientists have shed light on how changes to specific genes alter the coordinated direction that these cells are laid out.
Read MoreIn a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word recognition, with no serious adverse events observed.
Read MoreNearly 24% of US adults ages 20 to 69 have features of their hearing tests in one or both ears that suggest hearing loss from loud noise, based on a 2017 study by researchers from the NIDCD and the Centers for Disease Control and Prevention (CDC).
Read MoreThe new technology is based on a recent hearing aid specification, Audio Streaming for Hearing Aids (ASHA) on Bluetooth Low Energy Connection-Oriented Channels, which Google has developed in collaboration with GN Hearing and Cochlear.
Read MoreThese funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss, the RESTORE trial, and to prepare for a European filing.
Read MoreThe proteins, described in a report published June 12 in “eLife,” may hold a key to future therapies to restore hearing in people with irreversible deafness. An article summarizing the research was published on the Johns Hopkins Medicine website.
Read More